2026-08-05T11:42:21Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/228012024-11-28T17:49:31Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16961col_20.500.12105_16967

00925njm 22002777a 4500 dc Samperiz, Gloria author Fanjul, Francisco author Valera, Jose Luis author López, Meritxell author Rios, Angel author Penaranda, Maria author Campins Rosselló, Antoni author Riera, Melchor author Agusti, Alvar author 2019-10-29 Introduction: Previous studies have reported that the rate of FEV1 decline over time is increased in HIV patients but the mechanisms underlying this observation are unclear. Since current HIV treatment with Highly Active Antiretroviral Therapy (HAART) results in very good immuneviral control, we hypothesized that HAART should normalize the elevated rate of FEV1 decline previously reported in HIV patients if it was somehow related to the immune alterations caused by HIV, particularly in never smokers or quitters, since smoking is a well established risk factor for accelerated FEV1 decline in the general population. Methods: We explored this hypothesis in a prospectively recruited cohort of 188 HIV (smoker and non-smoker) patients treated with HAART in Palma de Mallorca (Spain) and followed-up for 6 years. The cross-sectional characteristics of this cohort have been published elsewhere. Results: We found that: (1) HAART resulted in good immune-viral control; (2) the rate of FEV1 decline remained abnormally elevated, even in non-smokers and quitters; and, (3) alcohol abuse during follow-up was related to FEV1 decline in these patients. Discussion: Despite adequate immune-viral control by HAART, lung function decline remains increased in most HIV patients, even in non-smokers and quitters. Alcohol abuse is a preventable risk factor to decrease the accelerated FEV1 decline in this population. Sampériz Abad G, Fanjul F,Valera Felices JL, Lopez Zamora M, Rios Olivencia A, Peñaranda Vera M, et al. Increased rate of FEV1 decline in HIV patients despite effective treatment with HAART. PLoS One. 2019 Oct 29;14(10):e0224510. 10.1371/journal.pone.0224510 1932-6203 PloS One http://hdl.handle.net/20.500.13003/13653 31661533 L2003581522 2-s2.0-85074252861 https://hdl.handle.net/20.500.12105/22801 532653400037 Increased rate of FEV1 decline in HIV patients despite effective treatment with HAART